Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
435
extremely virulent Aspergillus species have developed defenses against complement attacks. They release proteases to break down complement factors, obtain
complement regulatory molecules from the host, and conceal themselves to avoid
detection. Complement system and Aspergillus have complex interactions that offer
potential avenues for future treatment methods that could assist treat IA (Speth and
Rambach 2012). In the end, creating solutions to restore antifungal immunity in
vulnerable patients depends on our ability to comprehend how these processes work
or fail in the context of immunosuppressive therapies (Mackel and Steele 2019).
When bacteria, fungi, and other microbes learn to resist the effects of drugs intended
to eradicate them, resistance to antimicrobial medicines develops. This suggests that
the germs are not eliminated and can continue to grow. Antibiotic resistance in AF
(A. fumigatus), a common mold in the environment and the main cause of invasive
mold infections in humans, is increasing.
Resistance can be classied as secondary (developing resistance during drug
exposure) or primary (fungal pathogen intrinsically resistant to antifungal drug).
While it has been seen, Aspergillus rarely develops primary or acquired azole resistance. Three isolates (recovered from a lung transplant patient) in a set of A. fumiga-
tus clinical isolates obtained from more than 100 individuals between 1945 and
1998 were resistant to itraconazole but susceptible to voriconazole (Parker et al.
2014; Chandrasekar 2005).
Patients with aspergillosis, particularly those with fungal balls in pre-formed
cavities, have tremendous fungal reproduction. In these situations, long-term antifungal medication exposure promotes the development of resistance and the transfer
of gene mutations to the proliferating spores. As a result, the greatest number of
isolates with lower susceptibility has been recorded in this patient group (RomeroOlivares etal. 2019). Antimicrobial resistance can arise from the usage of antifungals in any form. Managing the proper application of azoles in industry, agriculture,
and human medicine will be crucial to halting the development of antibiotic
resistance.
One typical mechanism leading to acquired resistance to antifungals is drug target
change. Resistance to azoles is caused by changes in the genes that encode
14-α-demethylase, the pharmacological target of azoles (Lee etal. 2023).
Continuous exposure of fungi-to-azolic chemicals would lead to the emergence
of acquired resistance to chemical compounds azoles. Two options have been put
out for its development based on this supposition: exposure of the patient to azoles
for agricultural applications during treatment or in the surrounding environment,
436
N. K. Borah et al.
which leads to a cross-resistance to azoles for therapeutic use (Romero-Olivares
etal. 2019).
There are two known mechanisms by which A. fumigatus can become resistant
to azoles (Warris et al. 2002).
• Within the body: When azole antifungals are taken for an extended length of
time, strains of AF may develop resistance, withstand therapy, and propagate
infection.
• Outside the body: Azole compounds employed as fungicides, which share chemical similarities with azole antifungal drugs, can expose strains of A. fumigatus
on decomposing plants in the environment. Azole resistance may develop in certain strains (Antimicrobial-Resistant Aspergillus 2023).
For other antibiotics, such as voriconazole or itraconazole, it has not been shown
that resistance in Aspergillus causes therapy failure in the clinical situation of IA.A
single case report documents IA in a patient with a persistent granulomatous condition undergoing 6 years of itraconazole therapy. In vitro testing revealed that the
pathogen was resistant to all azoles. Voriconazole at a high dose proved to be an
effective treatment for the illness. Serious voriconazole-resistant fungal infections,
primarily caused by Zygomyces, have been reported in a number of papers recently.
These infections occurred after prophylactic or empirical voriconazole medication
for recipients of stem-cell transplants. One might expect breakthrough infections
from azole-resistant organisms when azole use increases in critically ill hosts
(Chandrasekar 2005).
Except for A. terreus, resistance to polyenes is extremely rare in Aspergillus spe-
cies. While the majority of A. terreus isolates are susceptible to itraconazole or
voriconazole invitro, they tend to be resistant to amphotericin B (AmB). In the
treatment of neutropenic rabbits infected with A. terreus, posaconazole or itraconazole demonstrated superior outcomes compared to amphotericin B. Animals
treated with aspirin exhibited improved lifespan, reduced fungal load, and rapid
clearance of Aspergillus galactomannan antigenemia (Pierce and Lopez-Ribot
2013). One proposed explanation for the limited efcacy of amphotericin B was the
low level of ergosterol in the A. terreus cell membrane, a characteristic that extends
to humans, contributing to amphotericin B’s suboptimal performance
(Chandrasekar 2005).
The establishment of resistance throughout therapy is interesting, because AmB
had been the only medication utilized against IA in previous decades. Due to the
usual attribution of clinical failures to insufcient host defenses and the infrequent
availability of successive samples during an infection, it remains uncertain whether
acquired immunity to amphotericin B (AmB) develops during the therapy of
IA.According to the few information available, it is unusual for azole or polyene
resistance to develop during treatment (Moghaddam et al. 2009).
Since its discovery in 1729 by Pier Antonio Micheli, the genus Aspergillus is made
up of more than 340 species spread across many habitats and environments. Based on
numerous studies to examine the taxonomy and signicance of this genus, it has been
18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
437
regarded as one of the most signicant general fungi because of its high biodiversity and
value (Monod et al. 2002). The majority of Aspergillus are terricolous, which are thought
to be both human and plant diseases and are crucial to the breakdown of organic waste.
Notwithstanding Aspergillus species’ potential for disease, they play a signicant role in
the food, medicine, agriculture, and pharmaceutical industries (Table18.1).
Aspergillus is a genus that contains more than 185 species. Until date, approximately 40 different Aspergillus species have been identied as responsible for causing opportunistic infections in both humans and animals (Pfaller etal. 2007). Among
these, AF stands out as the most prevalent species associated with diseases within
the Aspergillus genus. In addition, there are several other Aspergillus species,
Field of work
Fermenter
industries
Medical Field A. fumigatus
Spoilage causing
organism
Wastewater
treatment
Chemical
engineering
Pharmacueticals A. terreus
Agriculture A. niger – Plant growth promoting
Petroleum
industry
Species Role played by Aspergillus
A. niger.
A. terreus
A. oryzae
A. avus
A. niger
A. niger – Causes black rot in
A.
sclerotiorum
A. niger – Biosorption Bilgi etal. (2023)
A. oryzae
A. ustus – Biodegradation of
– Citric acid fermentation
– Production of bio-based
chemicals
– Fermentation of soybeans
– Produces aatoxin
– Causes aspergillosis
– Causes ABPA
vegetables
– Causes boll rot of cotton
– Blight in trees
– Produces lipases
– Catalyzes fermentation for
bioremediation
– Production of itaconic
acid and lovastatin
– Increased production of
kojic acid
potential
– Purication of soil
contaminated with heavy
metals, oil spills and
microbial toxins
petroleum hydrocarbons
References
Wold and Suzuki (1976),
West (2023), Tong etal.
(2021), Hyejin Hyeon
etal. (2020), Behera
(2020) and Son and Park
(2024)
Schwarz etal. (2024) and
Gamalathge and Perera
(2023)
Gloria and Osarolai
(2023), Bibi Marzieh
Razavizadeh etal. (2024)
and Al-Ghazali etal.
(2023)
de Moura Dickel etal.
(2022); Liu (2021)
Huang etal. (2021) and
Suryadi etal. (2022)
Mattos etal. (2021) and
Nayak etal. (2020)
Benguenab and Chibani
(2021)
438
N. K. Borah et al.
including A. candidus, A. amstelodami,, A. quadrilineatus, A. carneus, A. granulosus, A. oryzae, A. restrictus, A. terreus, A. ustus, A. nidulans, A. niger, and A. versi-
color, which have also been linked to causing diseases (Dos Reis et al. 2021).
Signicantly, in individuals with weakened immune systems, including those
undergoing immunosuppressive therapy for autoimmune or cancer-related illnesses,
recipients of organ transplants, and individuals with Acquired Immunodeciency
Syndrome (AIDS), AF stands out as the predominant culprit for invasive fungal
infections (Ben-Ami etal. 2010; Walsh etal. 2008).
Aspergillus-related diseases encompass a wide range, presenting diverse clinical
manifestations. Examples includes Hypersensitivity Pneumonitis, Chronic
Necrotizing Pneumonia (PEN), IA (ABPA), Aspergilloma (mycetoma), Allergic
Aspergillus sinusitis, and ABPA.The severity and nature of illnesses resulting from
Aspergillus infection are signicantly impacted by individuals’ immune system sta-
tus. In those with compromised or weakened immune systems, these conditions
tend to manifest more severely and can pose life-threatening risks. Among these,
IA, characterized by its seriousness and often fatal outcomes, has the potential to
affect virtually any organ in the body (Kritsi et al. 2019; Segal and Walsh 2006).
Aspergillus conidia are inhaled from the environment and usually eliminated by
immune cells, such as macrophages and neutrophils. However, glucocorticoids can
impair this response, increasing the risk of Aspergillus infection. In neutrophildecient individuals, the fungus can transition to an invasive form, characterized by
hyphal growth, angioinvasion, thrombosis, and necrosis, leading to severe complications, particularly in immunocompromised individuals or those undergoing
immunosuppressive treatments, as represented in Fig.18.1.
AF that persists in the airways can cause a hypersensitivity reaction that can lead to
the indolent and potentially progressive disease known as ABPA.Individuals with
underlying diseases often present with symptoms, so it is crucial to take ABPA into
account when treating these patients (Agarwal 2009). Individuals who possess both
atopy (a genetic predisposition to allergic reactions) and either asthma or CF commonly develop a condition referred to as ABPA.The precise prevalence of ABPA
among individuals with CF and asthma is not denitively known, but it is generally
considered to be relatively low.
It affects around 1–15% of CF patients and approximately 2% of those with
asthma. Although there is some evidence, suggesting that in certain regions of the
world, the incidence of ABPA may increase during months with elevated mold
counts, and it is worth noting that ABPA can occur year-round. There is no conclusive evidence linking the occurrence of ABPA to the overall ambient levels of
Aspergillus spores. ABPA does not exhibit a discernible gender preference, meaning that it affects both males and females equally (Agarwal etal. 2016).
Genetically determined inammatory responses in atopic patients are likely the
mediating factor in their susceptibility to ABPA.Familial occurrence of ABPA is rare,
18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
439
despite the fact that atopy is an inherited trait (Iyalla 2015). People with asthma and
CF, two diseases closely linked to atopy, are most likely to experience ABPA.Atopic
dermatitis, allergic rhinitis and conjunctivitis, and food hypersensitivity are among the
other atopic conditions shown to be more common in patients with ABPA.A reaction
to Aspergillus that is allergic causes allergic fungal sinusitis. Allergy-induced fungal
sinusitis and allergic beta-polymorphonucleosis (ABPA) have been linked to atopy
and asthma, despite initial discord (Cullinan etal. 2003; Shah etal. 2001).
Elevated eosinophil counts, heightened levels of Aspergillus-specic and total
IgE, excessive mucus production, and the presence of chronic asthma constitute the
clinical characteristics of the syndrome. Individuals with ABPA, including those
diagnosed with CF, form a relatively small yet notable subset within the broader
population affected by chronic asthma. The primary clinical challenge posed by
ABPA is distinguishing patients with straightforward chronic asthma from those
who may have steroid-responsive asthma due to ABPA.The initial symptoms outlined in the illness’s description included chronic wheezing, pulmonary inltrates,
sputum and blood eosinophilia, fever, and the appearance of brown particles or
plugs in the sputum (Wark etal. 2004). Several decades later, seven key diagnostic
criteria for ABPA were established, including peripheral blood eosinophilia, elevated serum immunoglobulin E (IgE) concentrations, precipitating antibodies to
Aspergillus antigen, immediate scratch test reactivity to Aspergillus antigen, a history of pulmonary inltrates (transient or xed), and the presence of central
bronchiectasis.
ABPA exhibits a diverse epidemiological prole, impacting individuals with underlying respiratory conditions, notably asthma and CF.The prevalence of ABPA varies globally, with studies reporting differing rates. For instance, in populations with
severe asthma, the prevalence of ABPA has been estimated to range from 2% to
28% (Agarwal etal. 2013). The incidence is notably higher in patients with poorly
controlled or persistent asthma, highlighting the correlation between the severity of
440
N. K. Borah et al.
asthma and the likelihood of developing ABPA.ABPA is often diagnosed in adolescents and adults, with a reported male predominance in some studies. In a retrospective analysis of 176 patients with ABPA, the mean age at diagnosis was found to be
32years, and males constituted 55% of the study population. Environmental factors
also play a role in the epidemiology of ABPA (Brakhage 2005).Exposure to AF, the
primary causative fungus, varies based on geographic location and climatic conditions. Regions with high Aspergillus spore concentrations may experience an
increased prevalence of ABPA.As an example, research conducted in India revealed
that 8.9% of individuals diagnosed with asthma were found to have ABPA, underscoring the signicant regional differences in its prevalence (Agarwal etal. 2010).
The initial mention of ABPA in England dates back to 1952 when Hinson etal.
provided the rst description of the disease. Subsequently, in 1971, ABPA was
reported in India, marking the commencement of numerous documented cases
(Patterson etal. 2000). Notably, the incidence of allergic aspergillosis is considerably
higher in Britain compared to the United States. In the UK, it constitutes almost 80%
of cases involving pulmonary eosinophilia and asthma. In contrast, the contribution
of the United States has primarily involved isolated cases, with reports from Britain
documenting a series of up to 111 patients (Beijers et al. 2020). One possible explanation for this difference in disease occurrence could be attributed to the lower atmospheric concentration of AF in the United States. As noted by Soloman and Burge,
the atmospheric burden of A. fumigatus in their Midwestern location is notably lower
than that observed in the British Isles (Kritsi et al. 2019; Solomon etal. 1978).
The diagnostic challenges associated with ABPA contribute to potential underdi-
agnosis. The importance of greater awareness and better diagnostic strategies was
highlighted by a study done in the United States that found that ABPA was underdiagnosed in 46% of patients with asthma despite meeting the diagnostic criteria
(Stevens etal. 2003). In terms of outcomes, early and appropriate treatment is crucial for managing ABPA (Singla et al. 2020).The use of antifungal agents, corticosteroids, and immunomodulatory therapies has been shown to be effective. Despite
treatment, some individuals may experience chronic respiratory morbidity. Overall,
understanding the epidemiology of ABPA involves considering the interplay of
respiratory conditions, environmental factors, and regional variations in Aspergillus
exposure, underscoring the need for tailored diagnostic and management approaches.
Although initial attempts with amphotericin B, ketoconazole, and nystatin therapies
for ABPA were not highly effective, more recent antifungal agents, notably intraconazole, have displayed potential (Fournier 1987). Itraconazole signicantly
decreased the frequency of exacerbations, according to recent studies. It has been
demonstrated that more recent antifungal medications are quite effective against
Aspergillus species. For Aspergillus, azoles continue to be the favored class of antifungals. Voriconazole, a more recent agent in this class, has demonstrated superior
efcacy over itraconazole in treating various pulmonary diseases associated with
Aspergillus. Its usefulness in the ABPA has not been proven, though. Echinocandins
have good tolerability and are also effective therapeutic agents. Examples of these
18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
441
include capsofungin, micafungin, and anidulafungin (Parmar 2002; Ferrari
etal. 2004).
The most prevalent clinical manifestation of lung infections resulting from
Aspergillus species is the development of aspergillomas. This condition is also frequently associated with sarcoidosis, particularly in individuals with damaged lung
tissue. A potentially life-threatening complication of this infection is severe bleeding from the lungs, known as fatal hemoptysis. This bleeding occurs when
Aspergillus mycelia (fungal threads) grow within pre-existing lung cavities.
Remarkably, this typically occurs in patients with normal immune function who do
not exhibit any symptoms related to the infection. Importantly, aspergilloma does
not involve the invasion of lung tissues or blood vessels by these fungal threads.
These pre-existing cavities in which aspergillomas develop can be caused by a
variety of factors and medical conditions. These include infections by atypical
mycobacteria, the presence of bullous emphysema, lung trauma, ankylosing spondylitis, advanced stages of sarcoidosis, or other interstitial lung diseases, such as
pneumoconiosis. Conditions such as bronchiectasis observed in CF and ABPA can
also contribute to the creation of these cavities. Lung abscesses, cavitating lung
tumors, pulmonary infarctions, and Pneumocystis jirovecii pneumonia are among
the common factors leading to the development of these cystic cavities (Pierce and
Lopez-Ribot 2013; Kosmidis and Denning 2014).
Aspergillomas have been found in patients without a history of pre-existing
dilated lung spaces, although they are less common in people with strong immune
systems. Imaging methods play a major role in the initial diagnosis of aspergilloma.
A lung biopsy is typically not necessary for the clinical diagnosis of aspergilloma,
with radiographic features of the chest playing a crucial role in making a preliminary diagnosis. On radiographs, pulmonary aspergillomas appear as solid, spherical
masses with water-like density. These masses may occasionally move within an
oval or round cavity, and there is an airspace of varying size and shape that separates
the mass from the cavity wall (Regnard etal. 2000).
Aspergilloma, a complex pulmonary condition characterized by the formation of
fungal masses within pre-existing lung cavities, presents a distinctive epidemiological prole. The prevalence of aspergilloma varies globally, with studies reporting
diverse rates inuenced by geographic and demographic factors. In regions with a
high incidence of chronic respiratory conditions and pulmonary tuberculosis, aspergilloma is more commonly observed. As an example, a study conducted in India
reported a prevalence of approximately 2.4% for aspergilloma among patients with
pulmonary tuberculosis (Fernández-Rodríguez et al. 2019; Maurya etal. 2005). In
individuals with chronic pulmonary aspergillosis, the incidence of aspergilloma is
approximately 25%. An estimated 18/100,000 is the prevalence over a 5-year period
442
N. K. Borah et al.
worldwide. With higher recorded incidence and prevalence in Southeast Asia, the
western Pacic, and Africa, that equates to a 1.2 million patient global burden
(Denning etal. 2012). A much rarer case, reported to be 0.13%, is isolated aspergilloma without prior parenchymal disease. It is noteworthy that while invasive
Aspergillus disease is more prevalent in individuals with primary or acquired immunodeciency, aspergilloma is not frequently seen in individuals with HIV infection
(Addrizzo-Harris etal. 1997; Hinson etal. 1952).
The epidemiology of aspergilloma is intricately linked to underlying lung dis-
eases, particularly tuberculosis. In areas with a high prevalence of tuberculosis,
such as parts of Asia, Africa, and Eastern Europe, the occurrence of aspergilloma is
more prominent. Moreover, individuals with pre-existing lung cavities, frequently
stemming from previous tuberculosis infections, face an elevated risk of developing
aspergillomas. Demographic factors also contribute to the epidemiology of aspergilloma, with studies suggesting a male predominance. In a retrospective analysis of
240 aspergilloma patients, 74% were male (Gupta etal. 2013).
The clinical manifestation of aspergilloma often lacks symptoms, potentially
resulting in underdiagnosis. Diagnostic difculties arise from the absence of distinct symptoms, relying heavily on imaging studies for detection. Moreover, the
incidence of aspergilloma may be underreported in regions with limited access to
medical facilities. Surgical intervention is deemed the primary treatment for symptomatic cases; however, managing aspergilloma is intricate, and the selection of a
therapeutic approach hinges on diverse factors, including the patient’s overall health
and the extent of the disease (Denning etal. 2012).
There is a considerable chance of developing problems, even though aspergillomas
are frequently discovered by chance in a patient who is asymptomatic or only
slightly symptomatic. The decision between surgical and conservative treatment
options is thus made based on the patient’s natural history and the likelihood of
complications. Rafferty etal. observed that in 20% of cases of non-surgically treated
mycetomas, IA develops. Itraconazole is the medication most frequently used to
treat aspergilloma when surgery is not an option (Stevens etal. 2000). Nevertheless,
there are documented cases of A. fumigatus demonstrating resistance to itraconazole invitro. Instances of acquired resistance during prolonged therapy and de
novo resistance have been reported (Huan et al. 2023; Dannaoui 2001).
Despite voriconazole proving effective in the treatment of invasive pulmonary
aspergillosis (IPA), its use in treating aspergilloma has been limited. Voriconazole
can serve as an alternative to itraconazole therapy, even though it shares a similar
mechanism of action. It exhibits good in vitro activity against the majority of
itraconazole- resistant strains of A. fumigatus (Gupta and Rai 2020; Herbrecht etal.
2002). The 30-day postoperative mortality rate for patients with aspergilloma
involving only one lung and normal respiratory function ranges from 1% to 5%.
Conversely, relying solely on antifungal therapy for the treatment of simple or complex aspergilloma has demonstrated limited efcacy.
18 A Comprehensive and Intricate Dynamics of Aspergillus: Implications…
443
One characteristic that sets IPA apart is the proliferative growth of fungal mycelia
in the pulmonary parenchyma. The primary feature of the illness is the invasion of
fungal tissue, which is uncommon and usually appears when immunosuppression is
present. There are about 20 documented cases of healthy individuals in this situation. Hemorrhagic infarction may result from invasion of the pulmonary vasculature. Advanced AIDS, prolonged and high-dose corticosteroid therapy, cytotoxic
therapy, neutropenia, solid-organ transplantation, chronic granulomatous disease,
and hematological malignancy are among the factors that raise the risk of IA (Shahi
et al. 2015; Amchentsev etal. 2008).
Risk factors for IA include solid-organ transplantation, immunosuppressive
medication, high-dose systemic corticosteroids, AIDS, neutropenia, and hematopoietic stem-cell transplantation. For individuals at risk, initiating antifungal medication early and adopting an aggressive diagnostic strategy can be critical for their
survival. The lung is the most typical location for primary invasive disease, with the
central nervous system often serving as the secondary site of invasive disease (Walsh
etal. 2008).
In AIDS patients and recipients of lung transplants, Aspergillus commonly
induces severe airway inammation, leading to conditions such as bronchitis or
tracheobronchitis characterized by ulcers and membrane formation (Bassetti etal.
2010). Hyphae inltrate the respiratory tract and create plugs made of necrotic
debris, inammatory cells, and mycelia. Wheezing and dyspnea are caused by airway blockage caused by these plugs and the membranes. Ten percent of patients
with IA experience either tracheobronchitis or pneumonia in addition to their infection. HIV-positive patients may develop Aspergillus sinusitis. Empyemas, or pleural
effusions, are an uncommon sign of IA (Nathan etal. 2000).
Primary risk factors for invasive Aspergillosis:
(a) Extended neutropenia (neutrophil count <500cells/mm3 for more than 10days)
or impaired neutrophil function.
(b) Administration of corticosteroids, particularly for durations exceeding 3weeks
and at high doses.
(c) Transplantation, with the highest risk associated with lung and bone marrow
transplants.
(d) Hematologic malignancies, especially with a heightened risk in cases of
leukemia.
(e) Cytotoxic therapy.
(f) AIDS, where the risk escalates with lower CD4 counts.
The prevalence of IA exhibits considerable variation across diverse geographic
regions and demographic groups. Its occurrence is notably higher in areas characterized by a greater concentration of immunocompromised individuals. Within
populations at elevated risk, such as those with hematological cancers, the estimated
444
N. K. Borah et al.
incidence falls within the range of 5–25%. Several factors contribute to these varying rates, including the accessibility of antifungal prophylaxis and advancements in
medical treatments. The foremost susceptibility lies with individuals possessing
weakened immune systems, comprising those with hematological malignancies,
recipients of solid-organ or stem-cell transplants, individuals experiencing severe
neutropenia (markedly low white blood cell counts), and those undergoing prolonged corticosteroid therapy.
IA is notably associated with elevated mortality rates, particularly within highrisk patient cohorts. Annually, approximately 300,000 individuals are affected by
invasive mold infections (IA), exposing an additional 30million people to the risk
associated with Aspergillus species, a predominant cause of IA (Sabino etal. 2021;
Oishi and Ouchi 2022). As highlighted by A Vazquez etal. (2016), IA manifests as a
severe infection with a progressive nature, characterized by substantial morbidity
and mortality rates ranging from 30% to 85%. Early diagnosis is pivotal, potentially
elevating survival rates to 50%. Presently, IA stands out as a signicant clinical challenge within the realm of invasive fungal infections (Morris and Lim-Wilby 2008).
Over the past decade, various epidemiological factors have contributed to the escalating concern surrounding this condition. Numerous reports highlight a growing prevalence of IA in autopsy ndings worldwide, surpassing invasive candidiasis to become
the most prevalent fungal infection (Groll etal. 1996; Kume etal. 2006). The routine
use of uconazole for prophylaxis in the last decade has played a role in a notable
decrease in invasive candidiasis incidence but has concurrently led to the emergence
of IA as the predominant invasive fungal infection (van Burik etal. 1998).
Although it is widely acknowledged that the epidemiology of IA is intricate and
contentious issues persist, the exact proportion of patients contracting the infection
from alternative sources remains unclear. Remarkably, a substantial proportion of
instances involving IA in allogeneic stem-cell transplant recipients occur in outpatient settings. These patients, who undergo prolonged periods of severe immunosuppression after engraftment, with alternating spells of hospitalization and
residence at home, consistently exposed to potent immunosuppressive therapies,
pose challenges in pinpointing the precise origin of the infection in individual cases
(Alonso etal. 2006).
Effectively managing IA involves a multifaceted approach that includes immunomodulation, early initiation of antifungal therapy, and, in certain scenarios, surgical
intervention. There are three main classes of antifungal agents for treating aspergillosis: azoles, echinocandins, and polyenes. The primary antifungal medication utilized in patients with IA is amphotericin B deoxycholate. It is crucial to administer
this medication at the highest tolerated doses, such as 1–3mg/kg/d, and to continue
treatment even if there is a slight increase in serum creatinine levels. In cases where
renal function is compromised or if nephrotoxicity occurs with deoxycholate
amphotericin, lipid formulations of the drug are recommended (Upton etal. 2007;
Cornely etal. 2007).